Invivyd (IVVD) Cash from Financing Activities (2021 - 2025)
Invivyd's (IVVD) quarterly Cash from Financing Activities came in at $157.2 million in Q4 2025, up 204025.97% YoY from N/an in Q4 2024, and up 169.54% on a QoQ basis from $58.3 million in Q3 2025.
Invivyd (IVVD) Cash from Financing Activities (2021 - 2025) Analysis & Trends
Invivyd (IVVD) has 5 years of Cash from Financing Activities data on file, last reported at $157.2 million in Q4 2025.
- Quarterly Cash from Financing Activities rose 204025.97% year-over-year to $157.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $215.6 million (up 448.24% YoY) and the FY2025 annual result came in at $215.6 million, up 448.24% from the prior year.
- Cash from Financing Activities grew to $157.2 million in Q4 2025, from $58.3 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $334.8 million in Q2 2021 to a low of -$749000.0 in Q4 2021.
- A 5-year average of $48.4 million and a median of $141000.0 in 2022 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities plunged 99.98% — and 2025, when it jumped 204025.97%.
- Tracing IVVD's Cash from Financing Activities over 5 years: stood at -$749000.0 in 2021, then surged by 118.83% to $141000.0 in 2022, then changed by 0.0% to $141000.0 in 2023, then plunged by 45.39% to $77000.0 in 2024, then jumped by 204025.97% to $157.2 million in 2025.
- The last three Cash from Financing Activities figures came in at $157.2 million (Q4 2025), $58.3 million (Q3 2025), and $131000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Invivyd | 212.23 Mn | 52.15 Mn | 13.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 157.18 Mn |
| Dec 31, 2025 | 157.18 Mn |
| Sep 30, 2025 | 58.31 Mn |
| Sep 30, 2025 | 58.31 Mn |
| Jun 30, 2025 | 131,000.00 |
| Jun 30, 2025 | 131,000.00 |
| Mar 31, 2025 | 10,000.00 |
| Mar 31, 2025 | 10,000.00 |
| Dec 31, 2024 | 77,000.00 |
| Dec 31, 2024 | 77,000.00 |
| Sep 30, 2024 | 61,000.00 |
| Sep 30, 2024 | 61,000.00 |
| Jun 30, 2024 | 92,000.00 |
| Jun 30, 2024 | 92,000.00 |
| Mar 31, 2024 | 39.10 Mn |
| Mar 31, 2024 | 39.10 Mn |
| Dec 31, 2023 | 141,000.00 |
| Dec 31, 2023 | 141,000.00 |
| Sep 30, 2023 | 92,000.00 |
| Sep 30, 2023 | 92,000.00 |